University of Cincinnati Cancer Center | Strategic Alliance Partners

The University of Cincinnati Cancer Center provides the overarching support for all cancer education and research efforts within the UC College of Medicine, UC Health, and Cincinnati Children’s to enhance collaboration among researchers and clinicians. Our vision is to build a nationally recognized center that excels in research, training, community impact, and that makes the most advanced care readily available to the people in the communities we serve.

Latest from University of Cincinnati Cancer Center


Preferences for Treating Relapsed HER2+ MBC

December 01, 2021

A panel of breast oncologists highlight their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.

Dr. John Byrd Presented the Binet-Rai Medal Award at XIX International Workshop on Chronic Lymphocytic Leukemia

September 21, 2021

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 07, 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

Dr. Herzog on the Use of HIPEC in Ovarian Cancer

October 09, 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

Maintenance Niraparib Improves PFS in Ovarian Cancer

June 29, 2016

Maintenance therapy with niraparib improved progression-free survival compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA mutation or homologous recombination deficiency.

Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC

September 30, 2015

John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.

Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell Lymphoma

September 22, 2015

Tahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).